Hypera S.A. at its Board of Directors meeting held on April 26, 2019, elected Luiz Eduardo Sales Clavis, executive of the Company since 2012, to occupy the position of the statutory vice-president responsible for the Company's commercial and marketing areas, as recommended by the board of directors. The company also announced that Mr. Adalmario Ghovatto Satheler do Couto, the Company's actual Investor Relations Officer (IRO), will also be responsible for the financial area of the Company (CFO), while Mrs. Vivian Karina Trujillo Angiolucci will be the Officer responsible for the Company's strategic planning and projects areas.
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.